Cyclosporine is a potent immunosuppressant widely used to prevent organ transplant rejection and treat autoimmune diseases such as rheumatoid arthritis and psoriasis.
As a calcineurin inhibitor, it suppresses T-cell activation and cytokine production, requiring careful therapeutic monitoring due to its narrow therapeutic index and potential for nephrotoxicity, hypertension, and drug interactions.
Cyclosporine is an immunosuppressive drug originally derived from a fungus first isolated from a soil sample in Norway, Tolypocladium inflatum gams.
Cyclosporine is a calcineurin inhibitor used primarily to prevent organ rejection in kidney, liver, and heart transplants. It also treats autoimmune diseases such as rheumatoid arthritis, psoriasis, and graft-versus-host disease (GVHD).
Its narrow therapeutic index necessitates careful monitoring due to risks of rejection, nephrotoxicity, and drug interactions.
Organ Transplant (Kidney, Liver, Heart):
Rheumatoid Arthritis: 2.5 mg/kg/day (max 4 mg/kg/day).
Severe Psoriasis: 2.5–4 mg/kg/day (taper if no response after six weeks).
Focal Segmental Glomerulosclerosis (FSGS): 3 mg/kg/day in two divided doses.
Off-Label Uses: GVHD, autoimmune hepatitis, ulcerative colitis, Crohn’s disease, and posterior uveitis.
Brand Name (Modified Cyclosporine, Microemulsion Formulation)
Brand Name (Non-Modified Cyclosporine, Original Formulation)
Generic Cyclosporine (Various Manufacturers)
Generic and brand-name cyclosporine formulations are not interchangeable due to differences in bioavailability and absorption.
Brand-name Neoral (a microemulsion formulation) provides more consistent and predictable drug levels compared to non-modified Sandimmune and some generics.
While FDA AB-rated generics fall within 80–125% bioequivalence, small variations in drug exposure may have serious clinical consequences for transplant patients, requiring therapeutic drug monitoring (TDM) to ensure safe conversion.
Some studies report that 18–20% of patients need dose adjustments when switching between formulations, increasing the risk of graft rejection or toxicity. Until more long-term data is available, clinicians should carefully supervise any formulation changes and ensure close patient-provider communication.
Administration guidelines for cyclosporine include:
Sandimmune (Non-Modified): Poor bioavailability; absorption depends on bile.
Neoral/Gengraf (Modified): Improved absorption; NOT interchangeable with Sandimmune.
Cyclosporine routes of administration include:
Oral: capsule or solution
IV: dilute in D5W or NS; infuse over 2-6 hours
Target Drug Levels (Trough, ng/mL):
The following labs should be regularly monitored in patients receiving cyclosporine:
The following adverse effects are relatively common with regular use of cyclosporine:
The following are contraindications to cyclosporine use in patients:
Absolute contraindications include hypersensitivity, severe renal impairment, uncontrolled hypertension, and active infection.
Relative contraindications include liver disease, pregnancy, and breastfeeding.
The following drug interactions may occur with cyclosporine and other medications:
Increased Cyclosporine Levels (Toxicity Risk): Macrolides, azoles, calcium channel blockers, and grapefruit juice.
Decreased Cyclosporine Levels (Rejection Risk): Rifampin, anticonvulsants, and St. John’s Wort.
Increased Nephrotoxicity Risk: NSAIDs, aminoglycosides, and amphotericin B.
Serious Interaction: Sirolimus should be administered 4 hours apart from cyclosporine.
Cyclosporine has certain black box warnings associated with its use:
⚠ High Risk of Malignancies & Serious Infections
⚠ Monitor Drug Levels to Prevent Toxicity or Rejection
⚠ Sandimmune ≠ Neoral – Do not interchange without physician approval
Symptoms of cyclosporine toxicity include vomiting, drowsiness, hypertension, hepatotoxicity, and edema.
Management for cyclosporine toxicity includes:
Cyclosporine levels are typically assessed through blood tests, with monitoring methods including:
Whole Blood Immunoassays: This should be done via a specific monoclonal immunoassay.
Chromatographic Techniques: High-performance liquid chromatography (HPLC) and liquid chromatography-tandem mass spectrometry (LC-MS/MS) offer precise quantification of cyclosporine and its metabolites.
Trough Level Testing: whole blood samples (not serum or plasma) are collected just before the next dose to determine the lowest concentration in circulation, guiding dose adjustments.
Peak Level Monitoring: In some cases, post-dose blood draws assess peak concentrations to evaluate absorption and metabolism, although samples obtained 2 hours post-dose may be more clinically relevant than general peak testing.
Elevated cyclosporine levels increase the risk of toxicity, which can manifest as:
Nephrotoxicity: Cyclosporine-induced kidney damage can lead to reduced glomerular filtration rate (GFR), electrolyte imbalances, and potential kidney failure.
Hypertension: Increased blood pressure is a common side effect associated with high drug levels.
Neurotoxicity: Symptoms such as tremors, confusion, and seizures can indicate excessive immunosuppression.
Infection Susceptibility: Over-suppression of the immune system increases vulnerability to opportunistic infections.
Possible Causes of Elevated Levels: Drug interactions (e.g., with azole antifungals or macrolide antibiotics), impaired liver function, and decreased cytochrome P450 metabolism can contribute to high cyclosporine levels.
Subtherapeutic cyclosporine levels can lead to inadequate immunosuppression, increasing the risk of:
Organ Rejection: Insufficient levels in transplant patients may trigger immune-mediated graft rejection.
Autoimmune Disease Flare-ups: In patients with conditions like rheumatoid arthritis or psoriasis, inadequate dosing may result in symptom relapse.
Possible Causes of Decreased Levels: Poor drug absorption, gastrointestinal conditions, genetic polymorphisms affecting metabolism, and drug interactions (e.g., with anticonvulsants or rifampin) can lower cyclosporine concentrations.
706556: Cyclosporine, Whole Blood | Labcorp. (2015). Labcorp. https://www.labcorp.com/tests/706556/cyclosporine-whole-blood
CYSPR - Overview: Cyclosporine, Blood. (2016). @Mayocliniclabs. https://www.mayocliniclabs.com/test-catalog/overview/35143#Specimen
Medline Plus. (2020, February). Cyclosporine: MedlinePlus Drug Information. Medlineplus.gov. https://medlineplus.gov/druginfo/meds/a601207.html
Mockli G, Kabra PM, Kurtz TW. Laboratory monitoring of cyclosporine levels: guidelines for the dermatologist. J Am Acad Dermatol. 1990 Dec;23(6 Pt 2):1275-8; discussion 1278-9. doi: 10.1016/0190-9622(90)70354-k. PMID: 2277135.
Morris RG. Cyclosporin therapeutic drug monitoring--an established service revisited. Clin Biochem Rev. 2003 May;24(2):33-46. PMID: 18568053; PMCID: PMC1855625.
Neoral. (2024, July 15). Medscape.com. https://reference.medscape.com/drug/neoral-sandimmune-cyclosporine-343196#0
Singh AK, Narsipur SS. Cyclosporine: A Commentary on Brand versus Generic Formulation Exchange. J Transplant. 2011;2011:480642. doi: 10.1155/2011/480642. Epub 2011 Nov 17. PMID: 22174986; PMCID: PMC3235899.
Tapia C, Nessel TA, Zito PM. Cyclosporine. [Updated 2023 Aug 28]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482450/